Literature DB >> 29702203

RASAL2 inhibits tumor angiogenesis via p-AKT/ETS1 signaling in bladder cancer.

Ke Hui1, Shiqi Wu1, Yangyang Yue1, Yanan Gu1, Bing Guan1, Xinyang Wang1, Jer-Tsong Hsieh2, Luke S Chang1, Dalin He3, Kaijie Wu4.   

Abstract

Muscle-invasive or metastatic bladder cancer (BCa) is a life-threatening disease for patients, and tumor angiogenesis is believed to play a critical role in the progression of BCa. However, its underlying mechanism of tumor angiogenesis is still poorly understood. In this study, we discovered that RASAL2, a RAS GTPase activating protein, could inhibit BCa angiogenesis based on our shRNA/siRNA knockdown or ectopic cDNA expression experiments. Mechanistically, RASAL2 downregulation could enhance the phosphorylation of AKT and then subsequently upregulate the expression of ETS1 and VEGFA. Furthermore, there was a negative correlation between RASAL2 and VEGFA or CD31 expression in subcutaneous xenograft and human BCa specimens. Taken together, we provide a new insight into the molecular mechanism of BCa progression, in which RASAL2 can be a new therapeutic target.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  AKT/ETS1 signaling; Angiogenesis; Bladder cancer; RASAL2; VEGFA

Mesh:

Substances:

Year:  2018        PMID: 29702203     DOI: 10.1016/j.cellsig.2018.04.006

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  8 in total

1.  RASAL2 regulates the cell cycle and cyclin D1 expression through PI3K/AKT signalling in prostate tumorigenesis.

Authors:  Qi Wang; Shiqi Wu; Yanan Gu; Hua Liang; Fei He; Xinyang Wang; Dalin He; Kaijie Wu
Journal:  Cell Death Discov       Date:  2022-06-06

Review 2.  Pumping the brakes on RAS - negative regulators and death effectors of RAS.

Authors:  Desmond R Harrell Stewart; Geoffrey J Clark
Journal:  J Cell Sci       Date:  2020-02-10       Impact factor: 5.285

3.  Evolutionary rate covariation analysis of E-cadherin identifies Raskol as a regulator of cell adhesion and actin dynamics in Drosophila.

Authors:  Qanber Raza; Jae Young Choi; Yang Li; Roisin M O'Dowd; Simon C Watkins; Maria Chikina; Yang Hong; Nathan L Clark; Adam V Kwiatkowski
Journal:  PLoS Genet       Date:  2019-02-14       Impact factor: 5.917

4.  RASAL2 suppresses the proliferative and invasive ability of PC3 prostate cancer cells.

Authors:  Krishma Tailor; Joseph Paul; Somiranjan Ghosh; Namita Kumari; Bernard Kwabi-Addo
Journal:  Oncotarget       Date:  2021-12-21

5.  RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma.

Authors:  Yangyang Yue; Kaijie Wu; Weikun Qian; Zeen Zhu; Simei Zhang; Wunai Zhang; Weifan Zhang; Shuai Wu; Li Li; Zheng Wu; Qingyong Ma; Keping Xie; Zheng Wang
Journal:  Int J Biol Sci       Date:  2022-06-27       Impact factor: 10.750

6.  PRKAA/AMPKα phosphorylation switches the role of RASAL2 from a suppressor to an activator of autophagy.

Authors:  Yong Bao; Christopher Qian; Meng-Yue Liu; Fei Jiang; Xiaoxiao Jiang; Huijuan Liu; Zhuqing Zhang; Fanghui Sun; Ningwei Fu; Zhaoyuan Hou; Ya Ke; Yan Li; Zhong-Ming Qian
Journal:  Autophagy       Date:  2021-02-24       Impact factor: 16.016

Review 7.  RASAL2 Plays Inconsistent Roles in Different Cancers.

Authors:  Bolun Zhou; Wei Zhu; Xingjun Jiang; Caiping Ren
Journal:  Front Oncol       Date:  2019-11-13       Impact factor: 6.244

8.  Knockdown of MCM8 inhibits development and progression of bladder cancer in vitro and in vivo.

Authors:  Wei Zhu; Fei Gao; Hongyi Zhou; Ke Jin; Jianfeng Shao; Zhuoqun Xu
Journal:  Cancer Cell Int       Date:  2021-04-30       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.